New clinical findings suggest that GLP‑1 receptor agonists and SGLT‑2 inhibitors may significantly slow kidney‑function decline in people with type 2 diabetes and albuminuria. Researchers highlight that these medications could reshape long‑term treatment strategies for diabetic kidney disease.
About the Author
